Efficacy and safety of conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-interstitial lung disease: A narrative review
The range of therapeutic options available for rheumatoid arthritis (RA) is becoming increasingly diverse. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs), biologic DMARDs, and targeted synthetic DMARDs offer the rheumatologist a far greater breadth of treatment options than be...
Saved in:
Main Authors: | Richard Conway, Luke Corcoran, Elena Nikiphorou |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-01-01
|
Series: | Indian Journal of Rheumatology |
Subjects: | |
Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2021;volume=16;issue=5;spage=92;epage=100;aulast=Conway |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
by: Abhishek Zanwar, et al.
Published: (2017-01-01) -
Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study
by: Małgorzata Wisłowska
Published: (2024-11-01) -
Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?
by: Beatrice Maranini, et al.
Published: (2025-01-01) -
Targeted Therapy for Rheumatoid Arthritis in the New Era
by: WANG Jun, et al.
Published: (2025-01-01) -
Warrick score in rheumatoid-arthritis interstitial lung disease: a promising tool for assessing the extent and progression of lung involvement
by: Duygu Temiz Karadag, et al.
Published: (2025-01-01)